Company Analysis
Sign in

TG Therapeutics, Inc. (TGTX)

Nasdaq: TGTX · Pharmaceutical Preparations · New York, NY · filing with the SEC since 1996
Full chart Alerts Compare
Grade7.3
◀ Past 6.5● Present 8.6▶ Future 6.2
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

8 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to TG Therapeutics, Inc.’s names, not what it holds today.

Patents granted
8
8 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 2 in 2024 and 2 in 2023
Applications published
10
since 2001, to Dec 31, 2025
Names they are printed under
4
its own name, a subsidiary, a former name
By yearGrantedApplications published
'02'11'15'17'19'20'21'22'23'24
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals4
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
TG Therapeutics, Inc. its own name
US, as the owner printed on each patent
7 granted
1 published
TG Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
8 published
Ariston Pharmaceuticals a subsidiary
US, as the owner printed on each patent
0 granted
1 published
Atlantic Technology Ventures, Inc. a former name
US, as the owner printed on each patent
1 granted
0 published
Names not counted (1)
MANHATTAN PHARMACEUTICALS INC
No country is printed for it. 0 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Apr 23, 202411,965,032Anti-CD20 antibody compositionsBiotechnologyTG Therapeutics, Inc.
Jan 30, 202411,884,740Anti-CD20 antibody compositionsPharmaceuticalsTG Therapeutics, Inc.
Nov 14, 202311,814,439Anti-CD20 antibody compositionsPharmaceuticalsTG Therapeutics, Inc.
Nov 7, 202311,807,689Anti-CD20 antibody compositionsPharmaceuticalsTG Therapeutics, Inc.
Apr 6, 202110,966,977Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disordersPharmaceuticalsTG Therapeutics, Inc.
Aug 4, 202010,729,768Combination of anti-CD20 antibody and PI3 kinase selective inhibitorPharmaceuticalsTG Therapeutics, Inc.
Jul 4, 20179,694,071Combination of anti-CD20 antibody and PI3 kinase selective inhibitorPharmaceuticalsTG Therapeutics, Inc.
Mar 12, 20026,355,650(3R,4R)-&Dgr;8-tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesicsPharmaceuticalsAtlantic Technology Ventures, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Aug 15, 20242024/0270863ANTI-CD20 ANTIBODY COMPOSITIONSBiotechnologyTG Therapeutics, Inc.
Jun 27, 20242024/0209110ANTI-CD20 ANTIBODY COMPOSITIONSBiotechnologyTG Therapeutics, Inc.
May 12, 20222022/0143026TRIPLE COMBINATION TO TREAT B-CELL MALIGNANCIESPharmaceuticalsTG Therapeutics, Inc.
Jun 10, 20212021/0169878COMBINATION OF ANTI-CD20 ANTIBODY, P13 KINASE-DELTA SELECTIVE INHIBITOR, AND BTK INHIBITOR TO TREAT B-CELL PROLIFERATIVE DISORDERSPharmaceuticalsTG Therapeutics, Inc.
Oct 15, 20202020/0323981Combination of Anti-CD20 Antibody and PI3 Kinase Selective InhibitorPharmaceuticalsTG Therapeutics, Inc.
Aug 15, 20192019/0247399COMBINATION OF AN ANTI-CD20 ANTIBODY, PI3 KINASE-DELTA INHIBITOR, AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY FOR TREATING HEMATOLOGICAL CANCERSPharmaceuticalsTG Therapeutics, Inc.
Jun 13, 20192019/0175592COMBINATION OF ANTI-CD20 ANTIBODY, P13 KINASE-DELTA SELECTIVE INHIBITOR, AND BTK INHIBITOR TO TREAT B-CELL PROLIFERATIVE DISORDERSPharmaceuticalsTG Therapeutics, Inc. · patent 10,966,977 granted from it
Oct 26, 20172017/0304441Combination of Anti-CD20 Antibody and PI3 Kinase Selective InhibitorPharmaceuticalsTG Therapeutics, Inc. · patent 10,729,768 granted from it
Oct 15, 20152015/0290317Combination of Anti-CD20 Antibody and PI3 Kinase Selective InhibitorPharmaceuticalsTG Therapeutics, Inc. · patent 9,694,071 granted from it
May 12, 20112011/0112010OCTANOIC ACID FORMULATIONS AND METHODS OF TREATMENT USING THE SAMEPharmaceuticalsAriston Pharmaceuticals
What it applied for, 2024 to 2025: Biotechnology 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton TGTX · research, not advice